This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DURECT Receives Complete Response Letter From FDA For POSIDUR™ (SABERA®-Bupivacaine)

CUPERTINO, Calif., Feb. 12, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for POSIDUR (SABER ®-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia.   Based on its review, the FDA has determined that they cannot approve the NDA in its present form, stating the NDA does not contain sufficient information to demonstrate that POSIDUR is safe when used in the manner described in the proposed label, and the FDA has indicated that additional clinical safety studies need to be conducted.  DURECT is evaluating the issues described in the Complete Response Letter and plans to have further discussions with the FDA around them. 

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

"In the coming months, we intend to work with the FDA to gain more clarity on the next steps that would be required to address the issues cited in the Complete Response Letter," stated James E. Brown, DVM, President and CEO of DURECT Corporation. 

Conference Call and Webcast

A live audio webcast of a conference call will be broadcast over the internet at 8:30 a.m. Eastern Time on February 13 and is available by accessing DURECT's homepage at www.durect.com and clicking " Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the " Investor Relations" section.

About POSIDUR

POSIDUR is a post-operative pain relief depot that utilizes DURECT's patented SABER ® technology to deliver bupivacaine to provide up to three days of pain relief after surgery. We are in discussions with potential partners regarding licensing development and commercialization rights to POSIDUR, for which we hold worldwide rights.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,131.91 -396.12 -2.40%
S&P 500 1,919.34 -52.84 -2.68%
NASDAQ 4,653.3550 -123.1530 -2.58%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs